Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma

Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Zinzani, Pier Luigi, Ribrag, Vincent, Moskowitz, Craig H., Michot, Jean-Marie, Kuruvilla, John, Balakumaran, Arun, Zhang, Yayan, Chlosta, Sabine, Shipp, Margaret A., Armand, Philippe
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2017
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5766837/
https://ncbi.nlm.nih.gov/pubmed/28490569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-12-758383
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky